GlassScriptPhysician profile
Michael Waudo Wangia
NPI 1548495955
$25,088.54
in general payments reported to CMS, 2019-2025
39 companies · $12K in 2025
The $12K reported for 2025 was more than what 93% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,682 · 2020: $774 · 2021: $1,506 · 2022: $1,319 · 2023: $1,701 · 2024: $1,899 · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,800 · Food and Beverage: $5,807 · Travel and Lodging: $1,661 · Education: $540.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,800.00 |
| Food and Beverage | $5,806.74 |
| Travel and Lodging | $1,661.35 |
| Education | $540.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $10,041.16 | 2021-2025 | Bimzelx |
| Genzyme Corporation | $4,307.10 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,643.99 | 2019-2025 | Dupixent, Libtayo |
| Novartis Pharmaceuticals Corporation | $1,217.41 | 2019-2025 | |
| Abbvie INC. | $1,114.82 | 2019-2025 | Skyrizi, Rinvoq |
| Janssen Biotech, INC. | $944.47 | 2019-2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $854.29 | 2022-2025 | Sotyktu |
| Lilly USA, LLC | $621.96 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Pfizer INC. | $594.15 | 2020-2025 | |
| Organogenesis INC. | $482.62 | 2021-2025 | Puraply, Affinity |
| Sun Pharmaceutical Industries INC. | $333.73 | 2020-2025 | Ilumya |
| Galderma Laboratories, L.P. | $307.38 | 2021-2025 | Oracea, Aklief, Epsolay |
| Amgen INC. | $260.89 | 2021-2025 | Otezla, Otezla |
| Biofrontera INC. | $253.83 | 2019-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $194.12 | 2019-2021 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Wangia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.